Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Breast Neoplasms × gedatolisib × Clear all

Phase

Phase 1 3 Phase 3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Neoplasms 1 Prostatic Diseases 1 Male Urogenital Diseases 1 Genital Diseases, Male 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Breast Neoplasms 1

Interventions

Trastuzumab 56 Paclitaxel 54 Cyclophosphamide 38 pembrolizumab 31 Fulvestrant 29 Capecitabine 28 Carboplatin 26 Docetaxel 20 Letrozole 18 Doxorubicin 17 palbociclib 15 durvalumab 14 abemaciclib 14 pertuzumab 12 eribulin 11 Vinorelbine 11 Lapatinib 11 Gemcitabine 11 Filgrastim 11 Albumin-Bound Paclitaxel 11 ribociclib 10 Everolimus 10 Bevacizumab 10 Taxes 9 Radiotherapy 9 Peripheral Blood Stem Cell Transplantation 9 trastuzumab deruxtecan 8 olaparib 8 neratinib 8 fludarabine 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03400254 2020-04-28

GLACIER

Abramson Cancer Center at Penn Medicine

Phase 1/2 Withdrawn

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡